Partner with us
Reach the people who decide what gets funded
Syenza News is read by HTA bodies, payers, and the market access and health economics teams who turn evidence into coverage decisions. Not a general health audience — a working one.
Reach
Audience data to August 2026, from Google Analytics, Value Science Weekly campaign reports and LinkedIn.
Audience
Consulting, pharma and biotech together account for over half of reader organisations, and the company-size profile is a barbell: large enterprises and specialist consultancies in near-equal measure.
By industry
- Business consulting & services
- 21.5%
- Pharmaceutical manufacturing
- 19.6%
- Biotechnology research
- 11.8%
- Hospitals & health care
- 6.6%
- IT services & IT consulting
- 4.3%
- Research services
- 2.7%
- Market research
- 2.6%
- Medical equipment manufacturing
- 1.7%
By company size
- 5,001–10,000 employees
- 20.1%
- 1–10 employees
- 17.7%
- 10,001+ employees
- 16.6%
- 11–50 employees
- 11.1%
- 51–200 employees
- 7.1%
- 1,001–5,000 employees
- 7.1%
- 201–500 employees
- 3.7%
- 501–1,000 employees
- 2.3%
By region
North America brings the most readers; Europe and Africa read the most deeply. Both columns matter, so both are here.
| Region | Active users | Engagement |
|---|---|---|
| North America | 4,385 | 24.9% |
| Europe | 2,873 | 44.4% |
| Asia Pacific | 1,865 | 39.7% |
| Africa | 765 | 43.0% |
| Middle East | 357 | 40.8% |
| Latin America | 258 | 35.7% |
What they read
Topic clicks across the 29-topic editorial taxonomy. No single topic dominates: readers follow the full span from regulatory decision to reimbursement outcome, which is what makes placement next to a specific subject worth something.
- Oncology1,864 clicks
All cancers, drug names, DLBCL, melanoma, myeloma
- Regulatory1,525 clicks
FDA, EMA and CHMP approvals, guidance, market authorisation
- HTA1,409 clicks
NICE, IQWiG, cost-effectiveness, QALY, ICER, value assessment
- Obesity / metabolic1,355 clicks
Diabetes, GLP-1s, lipid disorders
- Pharma financials865 clicks
Revenue reports, acquisitions, growth projections
- Drug pricing863 clicks
MFN policy, VPAG, reference pricing, price negotiations
- Neurology824 clicks
Alzheimer's, Parkinson's, MS, migraine
- Real-world evidence818 clicks
RWE and data, clinical trials, patient-reported outcomes
- AI & digital721 clicks
Artificial intelligence, federated learning, digital health
- Health policy639 clicks
NHS 10-year plan, NHI Act, health reform, legislation
- Health economics590 clicks
Economic burden, indirect costs, pharmacoeconomics
- Vaccines582 clicks
HPV, pneumococcal, RSV
- HIV / infectious543 clicks
HIV prevention, TB, malaria, AMR
- Market access519 clicks
Reimbursement, payer coverage, formulary access
Ways to partner
Tell us the outcome you need and we will propose the shape. Rates and formats are set per engagement rather than from a card.
Brand awareness
Sustained presence alongside the HTA, pricing and market access coverage this audience already reads. Display across the site and the newsletter, with placement next to the topics your market actually follows.
Contact us ›Lead generation
Gated reports, webinars and research collaborations. Readers register with their work email and their role, so what you receive is a qualified contact rather than an anonymous click.
Contact us ›Thought leadership
Sponsored analysis held to the same editorial standards as the newsroom, clearly labelled as sponsored. We will not run anything we would not be comfortable being asked about afterwards.
Contact us ›Event partnership
Coverage and promotion around the conferences this audience plans its year around — ISPOR, HTAi, AMCP, DIA — including pre-event briefings and post-event analysis.
Contact us ›Standards you are buying into
Journal-grade standards
Content follows the progressive disclosure conventions of JAMA, The Lancet and ICMJE. Sources are named and claims are attributable.
Named accountability
Articles carry a named author. The founder is an editorial board member of the Journal of Medical Economics.
Human expert review
Every piece is reviewed by someone who works in health economics and market access, not generated and published unseen.
Let’s talk
Tell us what you are trying to reach and we will tell you honestly whether this audience is the right one. A full media kit with formats and rates is available on request.
Or write to [email protected].
Audience figures to August 2026. Sources: Google Analytics 4, Value Science Weekly campaign reports and LinkedIn. About the newsletter.